Noguchi, Saki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬剤学講座 (Shiba-Kyoritsu)

Position

Research Associate/Assistant Professor/Instructor

External Links

Academic Degrees 【 Display / hide

  • Ph.D.(Pharmacy), Keio University, Coursework, 2017.03

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy

 

Papers 【 Display / hide

  • Transplacental Pharmacokinetic Model of Digoxin Based on Ex Vivo Human Placental Perfusion Study

    Kurosawa K., Noguchi S., Nishimura T., Tomi M., Chiba K.

    Drug metabolism and disposition: the biological fate of chemicals (Drug metabolism and disposition: the biological fate of chemicals)  50 ( 3 ) 287 - 298 2022.03

     View Summary

    Digoxin is used as first-line therapy to treat fetal supraventricular tachycardia; however, because of the narrow therapeutic window, it is essential to estimate digoxin exposure in the fetus. The data from ex vivo human placental perfusion study are used to predict in vivo fetal exposure noninvasively, but the ex vivo fetal-to-maternal concentration (F:M) ratios observed in digoxin perfusion studies were much lower than those in vivo. In the present study, we developed a human transplacental pharmacokinetic model of digoxin using previously reported ex vivo human placental perfusion data. The model consists of maternal intervillous, fetal capillary, non-perfused tissue, and syncytiotrophoblast compartments, with multidrug resistance protein (MDR) 1 and influx transporter at the microvillous membrane (MVM) and influx and efflux transporters at the basal plasma membrane (BM). The model-predicted F:M ratio was 0.66, which is consistent with the mean in vivo value of 0.77 (95% confidence interval: 0.64-0.91). The time to achieve the steady state from the ex vivo perfusion study was estimated as 1,500 minutes, which is considerably longer than the reported ex vivo experimental durations, and this difference is considered to account for the inconsistency between ex vivo and in vivo F:M ratios. Reported digoxin concentrations in a drug-drug interaction study with MDR1 inhibitors quinidine and verapamil were consistent with the profiles simulated by our model incorporating inhibition of efflux transporter at the BM in addition to MVM. Our modeling and simulation approach should be a powerful tool to predict fetal exposure and DDIs in human placenta. SIGNIFICANCE STATEMENT: We developed a human transplacental pharmacokinetic model of digoxin based on ex vivo human placental perfusion studies in order to resolve inconsistencies between reported ex vivo and in vivo fetal-to-maternal concentration ratios. The model successfully predicted the in vivo fetal exposure to digoxin and the drug-drug interactions of digoxin and P-glycoprotein/multidrug resistance protein 1 inhibitors in human placenta.

  • Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin

    Fokina V.M, Patrikeeva S, Wang X.m, Noguchi S, Tomi M, König J, Ahmed M.S, Nanovskaya T

    Journal of Pharmaceutical Sciences (Journal of Pharmaceutical Sciences)  111 ( 2 ) 505 - 516 2022.02

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00223549

     View Summary

    Pravastatin is currently under evaluation for prevention of preeclampsia. Factors contributing to placental disposition of pravastatin are important in assessment of potential undesirable fetal effects. The purpose of this study was to identify the uptake transporters that contribute to the placental disposition of pravastatin. Our data revealed the expression of organic anion transporting polypeptide 1A2 (OATP1A2) and OATP2A1 in the apical, and OATP2B1 and OATP5A1 in the basolateral membranes of the placenta, while organic anion transporter 4 (OAT4) exhibited higher expression in basolateral membrane but was detected in both membranes. Preloading placental membrane vesicles with glutarate increased the uptake of pravastatin suggesting involvement of glutarate-dependent transporters such as OAT4. In the HEK293 cells overexpressing individual uptake transporters, OATP2A1, OATP1A2 and OAT4 were determined to accept pravastatin as a substrate at physiological pH, while the uptake of pravastatin by OATP2B1 (known to interact with pravastatin at acidic pH) and OATP5A1 was not detected at pH 7.4. These findings led us to propose that OATP1A2 and OATP2A1 are responsible for the placental uptake of pravastatin from the maternal circulation, while OAT4 mediates the passage of the drug across placental basolateral membrane in the fetal-to-maternal direction.

  • Limited Impact of Murine Placental MDR1 on Fetal Exposure of Certain Drugs Explained by Bypass Transfer Between Adjacent Syncytiotrophoblast Layers

    Fujita A., Noguchi S., Hamada R., Inoue S., Shimada T., Katakura S., Maruyama T., Sai Y., Nishimura T., Tomi M.

    Pharmaceutical Research (Pharmaceutical Research)   2022

    ISSN  07248741

     View Summary

    Purpose: Multidrug resistance protein 1 (MDR1) is located at the interface between two syncytiotrophoblast layers in rodent placenta, and may influence fetal drug distribution. Here, we quantitatively compare the functional impact per single MDR1 molecule of MDR1 at the placental barrier and blood-brain barrier in mice. Methods: MDR1A and MDR1B proteins were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Paclitaxel or digoxin was continuously administered to pregnant Mdr1a−/−/Mdr1b−/− or wild-type mice, and the drug concentrations in the maternal and fetal plasma and maternal brain were quantified by LC-MS/MS. Results: MDR1A and MDR1B proteins are expressed in the membrane of mouse placental labyrinth, and total MDR1 at the placental barrier amounts to about 30% of that at the blood-brain barrier. The fetal-to-maternal plasma concentration ratio of digoxin was only marginally affected in Mdr1a−/−/Mdr1b−/− mice, while that of paclitaxel showed a several-fold increase. No such difference between the two drugs was found in the maternal brain distribution. The impact per single MDR1 molecule on the fetal distribution of digoxin was calculated to be much lower than that on the brain distribution, but this was not the case for paclitaxel. Our pharmacokinetic model indicates that the impact of placental MDR1 is inversely correlated to the ratio of permeability through gap junctions connecting the two syncytiotrophoblast layers to passive diffusion permeability. Conclusion: Our findings indicate that murine placental MDR1 has a minimal influence on the fetal concentration of certain substrates, such as digoxin, due to bypass transfer, probably via connexin26 gap junctions.

  • MicroRNA-126 suppresses the invasion of trophoblast-model JEG-3 cells by targeting LIN28A

    Pan X, Noguchi S, Ando M, Nishimura T, Tomi M

    Biochemical and Biophysical Research Communications (Biochemical and Biophysical Research Communications)  545   132 - 137 2021.03

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0006291X

     View Summary

    © 2021 Elsevier Inc. Inadequate trophoblast invasion and impaired trophoblast-induced vascular remodeling are features of preeclampsia. In this context, an angiogenesis-related microRNA, miR-126, is abnormally expressed in preeclampsia placentas, but its role in trophoblast development remains unclear. The purpose of this study was to investigate the roles of miR-126 in the proliferation, migration, and invasion processes of trophoblast cells using the human choriocarcinoma-derived JEG-3 cell line as a model. The mRNA expression profiling of JEG-3 cells with and without miR-126 overexpression, in combination with bioinformatics analysis, identified LIN28A as a putative target of miR-126. The results of real-time RT-PCR and luciferase assay were consistent with this idea. Overexpression of miR-126 in JEG-3 cells decreased the invasive ability of the cells without affecting proliferation or migration. The invasiveness of JEG-3 cells was significantly reduced to a similar extent by knockdown of LIN28A with siRNA and by miR-126-overexpression-induced downregulation of LIN28A, although the level of LIN28A protein was much lower in the siLIN28A-transfected cells. These results indicate that miR-126 suppresses JEG-3 cell invasion by targeting LIN28A, and suggest that miR-126-mediated downregulation of LIN28A might contribute to the onset/deterioration of preeclampsia.

  • Fluorouracil Uptake in Triple-Negative Breast Cancer Cells: Negligible Contribution of Equilibrative Nucleoside Transporters 1 and 2

    Saki Noguchi, Akinori Takagi, Takahiro Tanaka, Yu Takahashi, Xiaole Pan, Yuka Kibayashi, Ryo Mizokami, Tomohiro Nishimura, Masatoshi Tomi

    Biopharmaceutics & Drug Disposition (Wiley)  42 ( 2-3 ) 85 - 93 2021.01

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1099-081X

     View Summary

    © 2021 John Wiley & Sons Ltd. Equilibrative nucleoside transporters (ENTs) 1 and 2 reportedly accept fluorouracil as a substrate. Here, we evaluated ENT1/2 expression at the messenger RNA (mRNA), protein, and functional levels in a panel of four triple-negative breast cancer (TNBC) cell lines, BT-549, Hs578T, MDA-MB-231, and MDA-MB-435, and we examined the relationship of the observed profiles to fluorouracil sensitivity. Nitrobenzylthioinosine (NBMPR) at 0.1 μM inhibits only ENT1, while dipyridamole at 10 μM or NBMPR at 100 μM inhibits both ENT1 and ENT2. We found that the uptake of [3H]uridine, a typical substrate of ENT1 and ENT2, was decreased to approximately 40% by 0.1 μM NBMPR. At 100 μM, NBMPR almost completely blocked the saturable uptake of [3H]uridine, but this does not imply a functional role of ENT2, because 10 μM dipyridamole showed similar inhibition to 0.1 μM NBMPR. Expression of ENT1 mRNA was almost 1 order of magnitude higher than that of ENT2 in all TNBC cell lines. Liquid chromatography-tandem mass spectrometry(LC-MS/MS) LC-MS/MS-based targeted protein quantification showed that ENT1 protein levels were in the range of 9.3–30 fmol/μg protein in plasma membrane fraction of TNBC cell lines, whereas ENT2 protein was below the detection limit. [3H]Fluorouracil uptake was insensitive to 0.1 μM NBMPR and 10 μM dipyridamole, suggesting a negligible contribution of ENT1 and ENT2 to fluorouracil uptake. The levels of ENT1 mRNA, ENT1 protein, ENT2 mRNA, and ENT1-mediated [3H]uridine uptake in the four TNBC cell lines showed no correlation with fluorouracil sensitivity. These results indicate that neither ENT1 nor ENT2 contributes significantly to the fluorouracil sensitivity of TNBC cell lines.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 【「今さら聞けない」をスッキリ解消する 妊娠・授乳と薬】[妊娠と薬]妊娠による生理学的変化と薬物動態

    西村 友宏, 野口 幸希

    薬事 ((株)じほう)  62 ( 4 ) 717 - 727 2020.03

    Other, Joint Work,  ISSN  0016-5980

     View Summary

    <Points>▼妊娠による生理学的変動は薬物血中濃度に影響を与えるため、投与量や投与頻度の調節が必要な場合がある。▼血漿容積の増加により血漿タンパク濃度が減少するため、血漿タンパク結合率が減少し、薬物の分布容積や消失速度の増大につながる。▼肝薬物代謝酵素の発現変動が起こるが、その変動は代謝酵素の分子種により異なる。▼糸球体濾過量の上昇により、腎排泄型薬物の消失が促進される。▼治療薬物モニタリング(TDM)対象薬物にはTDMを行うことが推奨され、また血中濃度の解釈は血漿タンパク結合率が変動していることを考慮する必要がある。(著者抄録)

Presentations 【 Display / hide

  • タダラフィルおよびシルデナフィルのマウス胎仔移行性比較と胎盤透過制御機構

    石井まり, 西村友宏, 野口幸希, 田中博明, 池田智明, 登美⻫俊

    第41回日本妊娠高血圧学会学術集会, 

    2021.12

    Oral presentation (general)

  • 副作用報告頻度に基づく低胎児毒性アンジオテンシンII受容体拮抗薬の探索と低胎盤透過性の要因

    西村 友宏, 石川 優, 野口 幸希, 登美 斉俊

    第41回日本妊娠高血圧学会学術集会, 

    2021.12

    Oral presentation (invited, special)

  • マウス胎盤におけるPGE2受容体の発現解析

    高橋 駿太, 稲垣 舞, 野口 幸希, 西村 友宏, 登美 斉俊

    第29回日本胎盤学会学術集会 (Web) , 

    2021.11

    Oral presentation (general)

  • LIN28A downregulation-mediated effect of miR126 on the invasion of JEG-3 choriocarcinoma cell

    Saki Noguchi, Xiaole Pan, Misuzu Ando, Tomohiro Nishimura, Masatoshi Tomi

    第29回日本胎盤学会学術集会, 

    2021.11

    Oral presentation (general)

  • Ex vivoヒト胎盤灌流試験を用いたジゴキシンのヒト胎盤薬物動態モデル

    黒沢 健, 千葉 康司, 野口 幸希, 西村 友宏, 登美 斉俊

    日本薬物動態学会第36回年会 (Web) , 

    2021.11

    Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 尿細管の両面動態にアプローチする先天性代謝疾患治療法の開拓

    2020.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 野口 幸希, Grant-in-Aid for Early-Career Scientists , Principal investigator

  • トリプトファンバランスに着目した食事による胎児成長支援戦略の構築

    2018.04
    -
    2021.03

    日本学術振興会, 科学研究費助成事業 基盤研究(B), 基盤研究(B), No Setting

     View Summary

    胎盤関門においてトリプトファン(Trp)輸送を担う可能性が高いLAT輸送体のタンパク発現分子数を定量した結果、ヒトおよびラット胎盤関門において、LAT1およびLAT2タンパクの発現分子数定量に成功した。ヒトではLAT1およびLAT2の発現分子数が共に高かったのに対し、ラットにおいてはLAT1の発現量がLAT2に比べて数倍高いことが示された。げっ歯類胎盤における免疫染色においても、LAT1は胎盤関門の母体側細胞膜において高く発現していたのに対し、LAT2の発現は明確には示されなかった。さらに、LAT1が同様に高く発現している血液脳関門においては、血中アミノ酸濃度の変動がLAT1を介した脳への輸送速度を制御していることを、実験的に明らかにした。これらの結果は、LAT基質アミノ酸の総量に対するTrp存在比率(%)で定義されるTrpインデックスが、胎児など組織関門で制御されている領域へのTrp供給量、そしてキヌレインおよびセロトニン濃度を規定するとの仮説をサポートする成果として、重要である。
    日本食品標準成分表に基づきTrpインデックスを算出したところ、食品の種類によってTrpインデックスは5倍以上異なっていた。得られたTrpインデックスに基づくと、Trp欠乏を補う食品としては通常、タンパク質に富み、Trpのアミノ酸スコアが100%を満たす魚・肉・大豆などが同列に推奨されるが、Trpインデックスがより低い魚類や肉類と比較して、高い大豆が望ましいといったより適切な指導が可能となる。

  • 降圧薬同効薬間の有害事象報告頻度比較分析に基づく妊娠高血圧症治療薬開拓

    2018.04
    -
    2021.03

    日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), No Setting

     View Summary

    妊婦においては治療方法が限定的であり、有効な薬物治療法が確立されていない妊娠高血圧症候群に対して、現在は使用が禁忌とされている降圧薬の有効性、安全性を検証し、妊婦においても安全な降圧薬を見出すことを目的としている。これまでに臨床における副作用データベース検索によって、禁忌とされている降圧薬としてアンジオテンシンII受容体拮抗薬(ARB)のうちIrbesartanが比較的胎児に対して毒性を示す頻度が低い可能性を見出している。今年度は、ARB同効薬間で胎児移行性や副作用が異なる可能性を非臨床において検討した。ARBの胎児移行性は、ARB同効薬間で差が生じることを示すため、妊娠高血圧症を呈するモデルラットにおいてOlmesartanとIrbesartanを投与して血圧、母体血中濃度、胎児血中濃度等を評価した。OlmesartanおよびIrbesartanはいずれも母体の高血圧を改善した。胎児移行性はOlmesartanが高く、Irbesartanが低いことを見出し、胎児における血清アルブミンへの結合を考慮した非結合型血漿中濃度においてもIrbesartanは胎児移行性が低いことを見出した。また、Olmesartan投与時には当該妊娠高血圧症モデルラットが呈する胎児発育不全が改善されなかったのに対し、Irbesartan投与においては改善されたため、IrbesartanはARB同効薬の中でも比較的選択的に妊娠高血圧症の改善効果と低胎児毒性を表すことが示された。

  • 胎盤合胞体化と内分泌機能の成熟制御機構を標的とした妊娠合併症治療戦略

    2018.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 野口 幸希, Grant-in-Aid for Early-Career Scientists , Principal investigator

  • ヒト胎盤特異的輸送体による胎児環境制御機構の解明と病態時変動マーカーの探索

    2016.04
    -
    2017.03

    MEXT, JSPS, Grant-in-Aid for Scientific Research, 野口 幸希, Grant-in-Aid for JSPS Fellows, Principal investigator

     View Summary

    アンジオテンシンⅡ受容体拮抗薬(ARB) の胎児移行性にorganic anion transporter (OAT) 4が与える影響の評価とOAT4発現マーカーの探索を目的とし、OAT4を介した薬物輸送と胎盤特異的なOAT4の発現機構について検討した。ARBは、胎盤を透過して胎児腎に到達することでヒトに限定的な胎児毒性を示す。過去に、ARBであるolmesartanの胎盤関門胎児側基底細胞膜における輸送へのOAT4の関与について報告している。また、chlorideはOAT4を介した交換輸送の駆動力となることが提唱されることから、今回は、5種のARB (candesartan、irbesartan、losartan、telmisartan、valsartan)について、OAT4発現細胞による取り込みを、細胞外chloride非存在下で定量した。少なくともlosartan、candesartan、valsartanについては、OATを介した細胞内取り込みが示された。抗ヒスタミン薬cetirizineについてもOAT4を介した輸送方向性を解析し、OAT4がラセミ体のcetirizineのうち、levocetirizineのみを選択的に細胞内に取り込むことを示唆する結果を得た。OAT4の転写制御領域についての解析では、胎盤および腎臓由来OAT4 遺伝子の転写開始点が異なることを同定した。さらに、尿細管上皮および胎盤栄養膜モデル細胞における転写活性の比較から、胎盤におけるOAT4発現を司るプロモーター領域を明らにした。胎盤OAT4の5’隣接領域変異解析から、転写因子AP-2結合配列を含む領域が胎盤でのOAT4 基礎転写活性に必須の領域であることが示された。本研究より、ヒト胎児への薬物移行予測の発展に寄与する結果を得た。

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD: (PHARMACEUTICS)

    2022

  • SPECIAL PRACTICE IN TISSUE CULTURE AND GENE TECHNOLOGY

    2022

  • SEMINAR: (PHARMACEUTICS)

    2022

  • RESEARCH FOR BACHELOR'S THESIS 1

    2022

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2022

display all >>